All Posts Tagged With: "VRTX"
(BMY) Bristol-Myers Squibb Company Kicks Off 2012 Pharma Deals
The spate of acquisitions in the pharma industry continues in 2012 with Bristol-Myers Squibb Company (BMY) announcing the first major deal of the new year. Major merger and acquisition (M&A) deals have...
(JNJ) Pharma & Biotech Stock Review & Outlook – Industry Outlook
With 2011 coming to an end, the pharmaceutical industry continues to face challenges like sluggish prescription trends, EU pricing pressure, intensifying generic competition, pipeline failures and limited late-stage catalysts. The next five years are expected to reflect a...
(JNJ) Spotlight on Hepatitis-C Market
Is the hepatitis-C market the next Mecca for the pharma/biotech sector? It seems so if we go by the flurry of activity and heightened interest in this market in the past few quarters. The hepatitis-C virus (HCV) market seems to have caught the eye of several pharma/biotech...
(VRTX) Vertex Pharmaceuticals Riding High on Incivek Sales
Vertex Pharmaceuticals Inc. (VRTX) posted robust third quarter 2011 earnings (including stock-based compensation expense) of 56 cents per share, substantially above the Zacks Consensus Estimate of 19 cents...
(ENZN) Enzon Pharmaceuticals Plans a 50% Workforce Cut
Enzon Pharmaceuticals (ENZN) recently announced that it will reduce its workforce by almost half to better align its resources with much tempered pipeline activities. The research and development pipeline...
(EU) Pharmaceuticals Stock Outlook – September 2011 – Industry Outlook
The pharmaceutical industry continues to be impacted by major issues such as sluggish prescription trends, European Union (EU) pricing pressure, intensifying generic competition and limited late-stage catalysts. The next five years are expected to witness a significant imbalance...
(BMY) Bristol-Myers Squibb Presents HCV Data
Recently, Bristol-Myers Squibb Company (BMY) presented encouraging data from a phase II study (n=48) which evaluated its candidate BMS-790052 in combination with peginterferon and ribavirin (standards of care)...
(ENZN) Enzon Pharmaceuticals Analyst Downgrades Shares to Sell
We recently downgraded our rating on Enzon Pharmaceuticals Inc. (ENZN) from Neutral to Underperform with a target price of $9.50.
In mid-May 2011, Enzon announced plans to halt the development of its...
(VRTX) Vertex Pharmaceuticals Reports Positive Data
Vertex Pharmaceuticals Inc. (VRTX) reported positive data from a mid-stage trial on VX-509, which is being studied for the treatment of moderate to severe rheumatoid arthritis (RA). The 12-week study, which...
(ENZN) Enzon Pharmaceuticals’ Weak Top Line Widens Loss
Enzon Pharmaceuticals’ (ENZN) second quarter 2011 net loss of 12 cents per share (excluding restructuring charge) was wider than the loss of 8 cents suffered in the year-ago quarter as the decline in royalty...
(VRTX) Vertex Pharmaceuticals Loss Reduced by Incivek
Vertex Pharmaceuticals Inc. (VRTX) posted second quarter 2011 loss (including stock-based compensation expense) of 82 cents per share, narrower than the Zacks Consensus Estimate of 93 cents and the year-ago...
(MHS) Medco Health Solutions to Better Tackle Hepatitis C
Medco Health Solutions (MHS) is making attempts to curtail costs of treating patients suffering from hepatitis C (HCV). The company’s specialty pharmacy segment, Accredo Health Group, considers patient adherence...
(VRTX) Vertex Pharmaceuticals Get Positive Data on Incivek
Vertex Pharmaceuticals Inc. (VRTX) recently reported data from two late stage trials – ADVANCE and REALIZE – on Incivek (telaprevir). The data were published in the June edition of the New England...
(JNJ) Pharma & Biotech Stock Outlook – June 2011 – Industry Outlook
Challenges like sluggish prescription trends, EU pricing pressure, intensifying generic competition, pipeline failures and limited late-stage catalysts continue to impact the pharmaceutical industry. The next five years are expected to reflect a significant imbalance between...
(VRTX) Vertex Pharmaceuticals Posts Wider Loss
Vertex Pharmaceuticals Inc. (VRTX) posted first-quarter 2011 loss (including stock-based compensation expense) of $1.05 per share, in line with the Zacks Consensus Estimate, but wider than the year-ago loss...
(ENZN) Enzon Pharmaceuticals Analyst Holds Shares at Neutral
We have maintained our Neutral recommendation on Enzon Pharmaceuticals, Inc. (ENZN) with a target price of $12.00 after announcement of fourth quarter and full year 2010 results.
Enzon Pharmaceuticals’...
(CHS) Company News for February 24, 2011 – Corporate Summary
• Garmin Ltd. (NASDAQ:GRMN) reported Q4 EPS of $0.83, lower than the Zacks Consensus Estimate of $0.87 per share. Revenues for the quarter fell 21% year-over-year to $838.0 million, missing the Zacks Consensus Estimate...
(VRTX) Vertex Pharmaceuticals Reports Wider Loss
Vertex Pharmaceuticals Inc. (VRTX) posted a higher third-quarter loss (including stock-based compensation expense) of 99 cents per share, compared with the Zacks Consensus Estimate of a loss of 91 cents and...
(HGSI) Human Genome Sciences Seeks Approval For Hepatitis C Treatment
Human Genome Sciences, Inc. (HGSI) recently announced the submission of a Marketing Authorization Application, [MAA], to the European Medicines Agency (EMEA) seeking marketing approval of Joulferon (albinterferon...
(ARRY) Array BioPharma Sees Positive Results for ARRY-380
Recently, Array BioPharma Inc. (ARRY) announced positive interim results on its inhibitor, ARRY-380, from an early-stage, open-label, multiple dose trial in patients with advanced cancer. The company presented...
(VRTX) Vertex Pharmaceuticals Posts Wider Loss
Vertex Pharmaceuticals (VRTX) posted a loss of 83 cents per share in the third quarter, 3 cents wider than the Zacks Consensus Estimate of a loss of 80 cents. The company posted a loss of 92 cents per share...
(GSK) Inhibitex Coverage Initiated at Neutral
We are initiating coverage of Inhibitex (INHX) with a ‘Neutral’ rating and $2 price target. Our neutral rating stems from the very early-stage nature of the company’s pipeline — leading candidate FV-100 is currently in phase II testing —...
(ANDS) Anadys Begins Mid-Stage Trial
Yesterday, Anadys Pharmaceuticals Inc. (ANDS) started a 12-week phase II trial of its ANA598 for hepatitis C patients. ANA 598 will be evaluated in combination with interferon-alpha and ribavirin (current standard of care) in the mid-stage study. Data from...